Bernhard Lampert, PhD
About Bernhard Lampert, PhD
Bernhard Lampert, PhD, is the VP of Pharmaceutical Development with over 30 years of experience in drug development across pharmaceutical and biotech industries.
VP of Pharmaceutical Development
Bernhard Lampert, PhD, currently serves as the Vice President of Pharmaceutical Development. With a wealth of experience in the pharmaceutical and biotechnology industries, he oversees the entire drug development process. His role involves ensuring that all phases of drug development, from initial research through clinical trials, adhere to regulatory standards and scientific rigor.
Over 30 Years of Drug Development Experience
Bernhard Lampert brings over three decades of experience in drug development to his role. His extensive background includes multiple facets of the pharmaceutical and biotech industries. This long-standing tenure in the field underscores his comprehensive expertise in developing pharmaceuticals, driving innovations, and improving therapeutic outcomes.
Former Positions at Gilead and GSK
Before his current role, Bernhard Lampert spent 10 years in large, fully integrated pharmaceutical companies. His experience includes notable tenures at Gilead Sciences and GlaxoSmithKline (GSK). At these organizations, he gained critical insights into high-level pharmaceutical operations, contributing significantly to their drug development programs.
PhD in Medicinal Chemistry from University of Georgia
Bernhard Lampert earned his PhD in Medicinal Chemistry from the University of Georgia in 1989. This advanced degree laid the foundation for his career in drug development, providing him with the scientific and technical knowledge required to excel in the field. His academic background continues to influence his approach to pharmaceutical development.
Contributor to Scientific Literature and Patents
Bernhard Lampert has authored and co-authored numerous publications in peer-reviewed journals, contributing to the scientific community’s understanding of pharmaceutical development. Additionally, he is a co-inventor on patents related to the manufacture of antiviral drugs, highlighting his innovative contributions to the field of medicinal chemistry.